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Abstract
The serine proteinase inhibitor α-1 antitrypsin (AAT) is 
produced principally by the liver at the rate of 2 g/d. It 
is secreted into the circulation and provides an antipro-
tease protective screen throughout the body but most 
importantly in the lung, where it can neutralise the activ-
ity of the serine protease neutrophil elastase. Mutations 
leading to deficiency in AAT are associated with liver and 
lung disease. The most notable is the Z AAT mutation, 
which encodes a misfolded variant of the AAT protein 
in which the glutamic acid at position 342 is replaced 
by a lysine. More than 95% of all individuals with AAT 
deficiency carry at least one Z allele. ZAAT protein is not 
secreted effectively and accumulates intracellularly in the 
endoplasmic reticulum (ER) of hepatocytes and other 
AAT-producing cells. This results in a loss of function as-
sociated with decreased circulating and intrapulmonary 
levels of AAT. However, the misfolded protein acquires 
a toxic gain of function that impacts on the ER. A major 
function of the ER is to ensure correct protein folding. 
ZAAT interferes with this function and promotes ER 
stress responses and inflammation. Here the signalling 
pathways activated during ER stress in response to accu-
mulation of ZAAT are described and therapeutic strate-
gies that can potentially relieve ER stress are discussed. 
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Conformational disorders are characterised by protein 
misfolding and are dependent on the accumulation or 
localisation of  specific misfolded proteins to various 
cellular organelles. These disorders are caused by inherited 
or acquired modifications in protein folding culminating in 
accumulation of  aberrant protein conformers and include 
metabolic disorders such as diabetes, the neurological 
disorders Alzheimer’s and Huntington’s diseases as well as 
a number of  pulmonary disorders such as cystic fibrosis 
and α-1 antichymotrypsin deficiency. α-1 antitrypsin (AAT) 
deficiency is a genetic conformational disease associated 
with accumulation of  misfolded AAT in the endoplasmic 
reticulum (ER) of  hepatocytes and other AAT-producing 
cells[1]. It predisposes sufferers to early onset emphysema 
or liver disease. It is the only known cause of  genetic 
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α-1 ANTITRYPSIN DEFICIENCY
AAT deficiency is a hereditary disorder associated with mu-
tations in the SERPINA1 gene that can affect the liver and 
the lungs. The most common disease-causing mutation is a 
single nucleotide polymorphism encoding a glutamic acid 
to lysine substitution at position 342 of  the mature pro-
tein (Glu342Lys) that leads to misfolding and intracellular 
polymerisation of  AAT. This ‘‘Z’’ mutation, as it is called, 
modifies the protein’s reactive centre loop enabling it to 
interact with another ZAAT molecule in a process that can 
continue until large polymers form[2,3]. The normal AAT 
protein is referred to MAAT; it and all other conformers 
are named based on their electrophoretic mobility in iso-
electric focusing gels and in some cases on the geographical 
location where they were first identified e.g. MMalton. MAAT 
is a serine proteinase inhibitor with activity against neutro-
phil elastase (NE), a powerful neutrophil-derived protease 
capable of  degrading a wide range of  soluble proteins and 
most connective tissue components of  the lung. Although 
up to 100 different AAT alleles have been identified it is the 
Z allele that is predominantly associated with disease.
In the 1970s the largest unbiased nationwide AAT 
deficiency screen of  newborns was carried out by Laurell 
and Sveger in Sweden[4]. Of  200 000 individuals studied 127 
were identified as being homozygous for the Z allele and 
have been studied since. Notwithstanding Sveger’s study, 
globally ZAAT deficiency is an under-diagnosed condition; 
many being diagnosed as non-responsive asthmatics or 
chronic obstructive pulmonary disease (COPD) sufferers. 
Since 1997 the World Health Organization together with 
the American Thoracic Society and European Respiratory 
Society have advocated targeted detection programmes for 
AAT deficiency in all COPD, non-responsive asthma and 
cryptogenic liver disease patients and also for first degree 
relatives of  AAT deficient individuals[5]. In Ireland emerging 
data from the national targeted detection programme, the 
only government funded AAT deficiency targeted detec-
tion programme, indicates that AAT deficiency is twice as 
prevalent as previously estimated with one of  the highest 
frequencies in Europe. These findings support the concept 
that AAT deficiency is not a rare disease but a disease that 
is rarely diagnosed.
Pathophysiology 
Although ZAAT deficiency is associated with lung and 
liver manifestations, both organs are rarely affected in the 
same individual. AAT deficiency is the most common 
genetic diagnosis in children undergoing liver transplanta-
tion[6,7]. It is also an important cause of  hepatocellular car-
cinoma in adults[8]. Even so there is a marked heterogeneity 
in the liver disease phenotype. The histological hallmark of  
the disease is the presence of  ZAAT-containing globules in 
some but not all hepatocytes. These glycoprotein-contain-
ing globules stain positive with periodic acid-Schiff  (PAS) 
after treatment with diastase[9]. Transgenic ZAAT mice (PiZ 
mice) can develop hepatic inflammation and carcinomas 
that are associated with evidence of  these characteristic 
intra-hepatocytic globules[10,11]. Although relatively little is 
known about the pathogenesis of  hepatocellular carcinoma 
in ZAAT deficiency, based on their observations in ZAAT 
mouse livers and studies on biopsies from ZZ homozy-
gous individuals Perlmutter et al[12] have proposed a model 
whereby increased hepatocellular proliferation occurs in 
resting globule-devoid hepatocytes in response to an un-
identified ‘‘trans’’ signal from adjacent globule-containing 
cells. It is these globule-devoid cells that proliferate and in 
which adenomas and later carcinomas develop[13,14]. 
In contrast to the liver disease which is believed to arise 
due to a toxic gain of  function resulting from intracellular 
accumulation of  ZAAT, the lung manifestations occur due 
to a loss of  function. The liver is the body’s major source 
of  AAT. Decreased AAT secretion from the liver, decreases 
circulating AAT levels and markedly diminishes the lungs’ 
anti-NE protective defences. This can lead to a number 
of  deleterious events. In addition to causing direct damage 
to airway epithelial cells, unchecked NE activity can pro-
mote goblet cell hyperplasia and enhance mucus secretion. 
Impaired mucociliary clearance, cleavage of  complement, 
immunoglobulins and cell surface receptors occurring as a 
direct result of  too much NE on the respiratory epithelial 
surface also has important consequences for innate im-
munity[15]. Efficient neutrophil killing of  microorganisms 
is also impaired. Clinically, ZAAT-related lung disease is 
associated with aggressive emphysema in the 4th and 5th 
decades which is aggravated by cigarette smoking[16].
Modifiers of liver disease
The variable clinical presentation among AAT deficient 
individuals suggests that genetic and environmental dis-
ease modifiers make an important contribution to disease 
severity and outcome. In Sveger’s study only 8%-10% of  
ZZ homozygotes developed clinically significant liver dis-
ease[17]. A study by Wu et al[18] demonstrated that there is a 
delay in intracellular disposal of  ZAAT after gene transfer 
into fibroblast cell lines from ZZ homozygotes with liver 
disease compared to cell lines from homozygotes without 
liver disease. This suggests that differences exist in the qual-
ity control recognition and/or disposal mechanisms for 
misfolded proteins in cells of  ZZ liver disease sufferers. 
ER mannosidase I (ERManI) is a quality control factor that 
plays a key role in the sorting and targeting of  misfolded 
glycoproteins for proteosomal degradation. ZAAT is a 
misfolded asparagine-linked secretory glycoprotein and as 
such, the removal of  mannose units from its N-linked gly-
cans represents a crucial early event in its disposal. ERManI 
plays a stochastic and rate limiting role in distinguishing and 
targeting ZAAT for degradation. Pan et al[19] have identified 
a G/A single nucleotide polymorphism (SNP) at position 
4567 of  ERManI that mediates translational suppression 
of  ERManI and have proposed that the ‘‘A’’ SNP can accel-
erate the onset of  end stage liver disease in AAT deficiency. 
They showed that substitution of  ‘‘A’’ for ‘‘G’’ disrupts a 
potential microRNA (miRNA) binding site for miR-205 
in ERManI, and suggest that this may facilitate negative 
regulation by other miRNAs and concomitant translational 
repression of  ERManI. Another potential gene modifier 
associated with ZAAT-related liver disease is regulator of  
G signaling 16 (RGS16) which is up regulated in the liver 
of  ZAAT-deficient individuals[20]. Interestingly the degree 
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of  up regulation of  RGS16 in vivo correlates with hepatic 
levels of  insoluble ZAAT. 
ENDOPLASMIC RETICULUM STRESS
A major area of  interest in the biology of  ZAAT deficiency 
is ER stress. The ER is an organelle which extends from 
the nuclear membrane. It is the site of  translation, folding, 
modification and transport of  membrane and secreted pro-
teins and consists of  an extensive membranous network of  
tubes and cisternae. Correct folding of  newly made pro-
teins is made possible by several ER-resident chaperones, 
foldases and enzymes including, for example, Hsc proteins, 
calnexin, calreticulin and protein disulfide isomerases. 
Properly folded proteins are transported from the ER to 
the Golgi apparatus via COPII vesicles. Incorrectly folded 
proteins become complexed with Bip/Grp78 and are tar-
geted to the Sec61/Derlin/p97 VCP channel located in the 
ER membrane for extrusion into the cytosol and degrada-
tion by proteosomal and non-proteosomal mechanisms[21]. 
Intracellular conditions such as increased temperature, high 
salt concentrations, unchecked protease activity and the 
presence of  other unfolded proteins can lead to intracel-
lular protein damage. Together with aberrant oxidative, 
glycation, nitrosylation or deamination events, these condi-
tions promote protein damage and possible misfolding in 
the ER. Chaperone proteins facilitate the recognition of  
these incorrectly folded proteins. Misfolded ZAAT protein 
accumulation in the ER of  hepatocytes and other AAT-
expressing cells is a hallmark of  ZAAT deficiency[6,22,23].
Perturbation of  ER homeostasis can induce ER stress 
and a number of  discrete signalling pathways can be acti-
vated as a result[1]. These include the unfolded protein re-
sponse (UPR) which is a conserved signalling pathway that 
measures unfolded protein levels in the ER and adjusts the 
production of  ER chaperones, foldases and degradation 
factors appropriately to keep levels of  misfolded proteins 
in the ER lumen acceptably low. ER stress can also lead to 
apoptotic cell death mediated by the activation of  specific 
caspases. A third signalling pathway activated in response 
to ER stress in the ER overload pathway (EOR). This 
is characterised by activation of  the transcription factor 
NFκB which regulates proinflammatory gene expression. 
Much is now known regarding the effect of  ZAAT expres-
sion on ER stress responses from studies done with cell 
culture models, human monocytes and airway epithelial 
cells, and human and animal liver biopsies[6,20, 22-30].
Endoplasmic reticulum overload response
The transcription factor NFκB is activated by a range of  
diverse stimuli. Many of  these engage cell surface recep-
tors and initiate intracellular signal transduction pathways 
that converge at IκB kinase (IKK). IKK can also be acti-
vated in response to accumulation of  misfolded proteins in 
the ER. This enzyme complex phosphorylates the NFκB 
inhibitory proteins IκB-α, -β and -γ on key serine residues, 
leading to their ubiquitination and ultimate recognition and 
degradation by the proteasome. After removal of  IκB pro-
tein, NFκB is free to translocate to the nucleus due the ex-
posure of  its nuclear localisation sequences, where it binds 
to NFκB recognition elements in the promoter of  target 
genes and promotes their transcription. 
We and others have investigated NFκB activation in 
the context of  ER accumulation of  misfolded ZAAT in 
Chinese hamster ovary (CHO) and 16HBE14o- human 
bronchial epithelial cell lines and in human monocytes[27,30]. 
In all cell types studied expression of  ZAAT is associated 
with activation of  NFκB. In liver cells in cell culture, ani-
mal models of  ZAAT deficiency and also in vivo in liver 
biopsies from ZZ homogygous individuals, NFκB activa-
tion has also been detected[26,29]. In liver cells it is feasible 
that activation of  NFκB in response to accumulation of  
ZAAT could mediate inflammation and neutrophil infiltra-
tion via up regulation of  interleukin-8. Given that NFκB is 
involved in inflammation-associated carcinogenesis, EOR 
is likely to have important role in the pathogenesis of  he-
patocellular carcinoma in ZAAT-deficient individuals[31].
Apoptosis
Although NFκB is largely cytoprotective, when the bal-
ance between the misfolded protein load in the ER and 
the ability to correct ER homeostasis cannot be restored, 
cell death may occur via apoptosis. This is the second ER 
stress-induced response. Apoptosis induced by ER stress 
differs from conventional apoptosis by the involvement of  
an ER-resident caspase, caspase-4[32]. Two other mecha-
nisms of  ER stress-induced apoptosis are associated with 
the UPR (see below) and involve PERK-CHOP-GADD34 
and IRE1-TRAF2-JNK. 
We evaluated ER stress-induced apoptosis in HEK293 
cells using the ER stress inducer thapsigargin and MAAT 
and ZAAT transgenes[28]. Our studies showed that, similar 
to thapsigargin treatment, expression of  ZAAT, but not 
MAAT, induced cleavage of  both procaspase-4 and down-
stream procaspase-7. However the role of  caspase-4 in 
ER stress-induced apoptosis appears to be stimulus- and 
cell type- specific. In order to evaluate its role in ZAAT-
induced cell death we performed gene knock-down stud-
ies using caspase-4 or GAPDH siRNAs. The caspase-4 
siRNA resulted in greater than 70% inhibition of  cas-
pase-4 protein production. However, surprisingly this did 
not promote cell survival in ZAAT expressing cells, nor 
did it inhibit ZAAT-induced caspase-7 activation. We con-
cluded that caspase-4 is not at the apex of  the ZAAT/ER-
induced apoptotic signalling pathway, nor is it essential for 
ER-mediated apoptosis in HEK293 cells and it is unlikely 
to represent a useful target for interfering with ER stress-
induced apoptosis by ZAAT. 
Using TUNEL staining, terminal apoptosis could be 
detected in HEK293 cells expressing ZAAT compared to 
mock-transfected cells[28]. In contrast to these in vitro studies, 
increased apoptosis has not been detected histologically or 
by TUNEL staining in the livers of  ZAAT mice. This may 
be related to the robust regenerative and cell survival prop-
erties of  hepatocytes and emphasizes once again the highly 
specific stimulus- and cell type-specific nature of  ER stress 
responses. The mechanism by which the caspase pathway 
is inhibited in globule-containing hepatocytes is not known 
but it could be related to the known antiapoptotic effects 
of  MAAT and ZAAT[30,33] which, in the case of  MAAT, are 
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related to direct binding and inhibition of  caspase-3. How 
ZAAT might gain access to caspase-3 in liver cells and in 
which cellular compartment this may occur are not known. 
Unfolded protein response
The third important pathway activated by ER stress is 
the unfolded protein response[21,34]. This is an integrated 
signalling network activated by ER stress. UPR governs 
repression of  translation and results in the synthesis of  
molecular chaperones, degradation factors and ER-resi-
dent enzymes, which co-operate to restore correct protein 
folding in the ER. If  this response fails, UPR activation may 
lead to induction of  ER-associated degradation (ERAD) to 
effectively remove terminally misfolded proteins.
Figure 1 summarises the major events that occur du-
ring UPR. Signalling involves three key ER membrane-
localised proteins PERK, ATF6 and IRE1 which are 
normally maintained in an inactive state by association with 
Bip/Grp78. In the presence of  misfolded proteins in the 
ER lumen, Bip is titrated away enabling oligomerization 
and activation of  each of  these factors. Activation of  
PERK results in phosphorylation and inactivation of  the 
eukaryotic initiation factor eIF2α which interferes with 
global protein synthesis via inhibiting eIF2B. Paradoxically 
this event actually enhances transcription and translation of  
the ATF4 transcription factor[35]. ATF4 induces expression 
of  the transcription factor CHOP (also called GADD153) 
which can trigger the dephosphorylation of  eIF2α via 
induction of  GADD34 which in turn stimulates protein 
phosphatase-1 (PP1)[36]. Prolonged CHOP activation can 
also lead to apoptosis characterised by a decrease in Bcl-2 
protein and translocation of  Bax from the cytosol to the 
mitochondria[37].
PERK can also directly phosphorylate Nrf2[38], a 
transcription factor that together with Maf  binds to anti-
oxidant response elements in the promoters of  many anti-
oxidative genes, and promotes their transcription[39]. Nrf2 
also has a role in regulating the proteasome system that 
degrades damaged and misfolded proteins, in particular the 
proteosomal subunit PSMB6[40]. Impaired Nrf2 signaling 
can significantly impair proteosomal activity and heighten 
ER stress responses in the airways. Malhotra et al[40] sug-
gest that pharmacological approaches which augment Nrf2 
activity may up-regulate antioxidant defenses, relieve ER 
stress, and could be important for treatment of  COPD. 
How this might affect the liver manifestations of  ER stress 
in the context of  intracellular accumulation of  ZAAT re-
mains unclear. 
Another cascade activated in the UPR involves ATF6 
(Figure 1). Full length ATF6p90 is transported to the 




































Figure 1  Unfolded protein response. Accumulation of misfolded proteins in the endoplasmic reticulum lumen (e.g. Z α-1 antitrypsin) titrates Bip/Grp78 away from PERK, 
ATF6 and IRE1. PERK dimerises, becomes phosphorylated and inactivates eIF2α by phosphorylation which blocks translation via eIF2B. ATF4 gene and protein expression 
is induced leading to ATF4-regulated gene expression, including GADD34 which stimulates protein phosphatase-1 (PP1) and triggers dephosphorylation of eIF2α. Nrf2 is 
phosphorylated and activated by PERK, translocates to the nucleus and induces antioxidant gene expression. ATF6 is transported to the Golgi and cleaved by the proteases 
S1P and S2P to generate the active ATF6p50 transcription factor which can activate expression of XBP1 and chaperone genes. IRE1 is phosphorylated, assembles into 
multimers and via its RNAse activity uses unspliced XBP1 (uXBP1) mRNA as a substrate to generate spliced XBP1 (XBP1s) mRNA which encodes a transcription factor that 
regulates expression of EDEM1 and chaperones.
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Golgi apparatus where it is cleaved by two proteases S1P 
and S2P[41] to generate a basic leucine zipper transcription 
factor ATF6p50 that migrates to the nucleus and activates 
transcription of  genes under the control of  ER stress re-
sponse elements (ERSE) e.g. Grp78, XBP-1.
IRE1 is an endoribonuclease that becomes activated 
by phosphorylation when it forms a dimer. Following its 
subsequent assembly into multimers IRE1 acquires RNAse 
activity and acts on XBP1 mRNA as a substrate[42]. The 
resulting alternatively spliced transcript encodes a tran-
scriptionally active 54kDa XBP1 protein which regulates 
the transcriptional induction of  important factors involved 
in degradation of  misfolded proteins e.g. ER degradation-
enhancing α-mannosidase-like protein (EDEM) 1. Mu-
limerisation of  IRE1 can also lead to JNK activation via 
TRAF2 and ASK1 and potentially promote apoptosis[34].
Although we know that all three arms of  the UPR can 
be activated in response to overexpression of  ZAAT in 
CHO, HEK293, HepG2 and 16HBE14o- cells[27-30] and 
basally in human peripheral blood monocytes isolated 
from ZZ homozygous individuals[23], these pathways do 
not appear to be activated in inducible models of  ZAAT 
deficiency liver disease or in liver cells in vivo. Indeed a 
number of  studies have failed to detect activation of  the 
UPR in cell culture and animal liver models of  ZAAT 
deficiency[20,26] and it has been speculated that the absence 
of  UPR signalling permits the survival of  cells that have 
accumulated high levels of  ZAAT i.e. globule-containing 
hepatocytes.
Recently it has emerged that ZAAT deficiency is also 
associated with aberrant immune cell function[23]. Periph-
eral blood monocytes express AAT. Carroll et al[23] have 
generated evidence for UPR activation in monocytes from 
individuals with ZAAT deficiency and link this phenom-
enon to an altered inflammatory response. Specifically 
ATF4, XBP-1 and a subset of  genes involved in the UPR 
are all increased in monocytes from ZZ compared to MM 
individuals. Expression of  these genes could be induced in 
MM monocytes by treatment with the ER stress inducer 
thapsigargin, linking the observed ZZ monocyte changes 
to ER stress. Confocal microscopy demonstrated that not 
only is ZAAT retained in the ER in ZZ monocytes but 
that GRP78 is also increased even in resting cells. These 
altered gene expression patterns contribute to enhanced 
basal and agonist-induced cytokine production by ZZ 
monocytes and activation, again, of  the NFκB pathway. 
Thus our current understanding of  the mechanisms regu-
lating ZAAT-related lung and liver disease should now be 
expanded to include of  a role for exaggerated inflamma-
tory responses by circulating blood cells.
REMOVAL OF MISFOLDED α-1 
ANTITRYPSIN 
There are at least two pathways for degradation of  ZAAT 
that accumulates in the ER, the proteosomal and autopha-
gic degradative pathways. Soluble ZAAT is degraded by 
the proteasome whilst polymerized ZAAT is degraded by 
autophagy[9].
Endoplasmic reticulum associated degradation
ERAD is the process which monitors the production of  
mutant glycosylated secretory proteins and directs them 
to the ubiquitin-proteasome system to be degraded[43]. 
The ER luminal and transmembrane proteins EDEM1, 
EDEM2 and EDEM 3 extract misfolded AAT from ER 
chaperones and facilitate enzymatic mannose trimming of  
its carbohydrate side-chain by ERManI[9]. The misfolded 
proteins are retro-translocated to the cytosol, modified 
with polyubiquitin and degraded by the proteasome. Up 
to 30% of  all newly synthesised proteins undergo degra-
dation by this process within minutes of  formation most 
likely because they are products of  unsuccessful folding or 
failures of  multimer assembly. When the level of  abnor-
mal proteins accumulating surpasses the ability of  a cell to 
degrade and dispose of  them, ER accumulation and ER 
stress ensue. This is classically seen in ZAAT deficiency 
where terminally misfolded ZAAT proteins and unas-
sembled complexes are eliminated by ERAD. 
Autophagy
The proteosomal pathway does not fully account for dis-
posal of  all ZAAT. In addition to ERAD ZAAT can also 
be degraded by autophagy[25], a cellular mechanism for the 
degradation of  cytoplasmic constituents within lysosomes. 
Autophagy is the process by which cytoplasmic constitu-
ents and intracellular organelles are sequestered within 
double membraned vesicles called autophagosomes that 
fuse with lysosomes to form autophagolysosomes, inside 
which their constituents are degraded. Three autophagy 
gene products ATG5, ATG6 and ATG16 are particularly 
important for this process and are necessary for the piece-
by-piece digestion of  aggregated ZAAT[44]. The presence 
of  aggregated rather than soluble ZAAT appears to spe-
cifically activate autophagy. Expansion and dilatation of  
the ER and increased numbers of  autophagosomes, two 
morphological changes characteristic of  autophagy, are evi-
dent in fibroblasts overexpressing ZAAT, in ZAAT mouse 
liver cells and liver cells from ZAAT individuals[6,22,24,25]. 
Autophagy also plays a role in the removal of  senescent or 
damaged mitochondria in a process termed ‘mitophagy’. 
This is likely to be an important process in the ZAAT 
deficient liver given that mitochondrial dysfunction and 
mitophagy have been observed in patient liver samples and 
mouse models[24].
Thus the current dogma regarding degradation of  
ZAAT involves two major mechanisms, ERAD and au-
tophagy. ERAD deals with removal of  soluble ZAAT that 
accumulates in the ER presumably bound to chaperones 
whilst autophagy is specialised for the polymerised and ag-
gregated forms of  ZAAT that accumulate constitutively 
but that become more abundant during the acute phase 
response when expression of  AAT is induced. 
POTENTIAL THERAPIES
Notwithstanding the fact that a small percentage of  ZAAT 
can be secreted from hepatocytes and fulfils a functional 
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role as an antiprotease in the body[45], there is a pressing 
need to design strategies to impair or prevent expression 
of  mutant ZAAT to counteract its deleterious effects on 
ER accumulation in hepatocytes and monocytes in particu-
lar where ZAAT ER accumulation has known effects. This 
is particularly important during episodes of  elevated AAT 
expression such as during infection or fever. A number of  
potential interventions likely to have therapeutic potential 
for the liver disease in ZAAT deficiency are under investi-
gation. These include a variety of  approaches. 
Surgical intervention
Liver transplantation for ZAAT deficiency is confounded 
by a number of  factors including donor availability and 
poor, but improving, survival rates. Hepatocyte transplan-
tation now offers hope for some ZAAT deficient liver 
patients and has been developed as an alternative to whole 
liver transplantation. Successful hepatocellular transplanta-
tion requires transplantation of  up to 5% of  the liver mass 
and can achieve 1%-5% repopulation of  the liver[9].
Endoplasmic reticulum stress relieving agents and 
inducers of apoptosis
A selection of  compounds that have the ability to allevi-
ate ER stress by a variety of  different mechanisms may 
be worth considering for the treatment of  ZAAT-related 
liver disease and to reverse the hyperinflammatory state 
of  ZAAT monocytes. Selenium is a trace mineral that can 
relieve a number of  indices of  ER stress in a HepG2 liver 
cells model over expressing ZAAT[29]. It mediates its effect 
in two ways; via inhibition of  NFκB activation through 
up regulated expression of  15deoxy-prostaglandin J2 and 
PPARγ, and by enhancing expression of  selenoproteins 
such as selenoprotein S which can participate in ERAD.
α-linolenic acid and palmitoleate are agents that in-
hibit UPR signals[46,47]. α-linolenic acid, for example can 
inhibit eIF2α phosphorylation and expression of  CHOP 
and GRP78 in rat renal cells. These agents are likely to be 
useful for treating the immune cell defects in ZZ individu-
als. However, since UPR is not activated in vivo in ZAAT 
deficient liver disease patients these agents are unlikely to 
have therapeutic benefit. Similarly, agents such as taurour-
sodeoxycholic acid (TUDCA) and salubrinal may prove 
to have more use in modulating ER stress in monocytes 
and possibly airway epithelial cells rather than liver cells. 
TUDCA is a bile acid that can inhibit ER stress-induced 
apoptosis[28]. Salubrinal can block cell death in response to 
UPR induction by preventing GADD34/PP1-mediated 
dephosphorylation of  eIF2α[48]. Given that it is desirable to 
induce rather than inhibit apoptosis in globule-containing 
hepatocytes, TUDCA and salubrinal have little relevance to 
liver disease in this context. However, at lower doses than 
are used for induction of  apoptosis they may have other 
desirable ER stress relieving properties.
Gene therapies
Ribozymes, peptide nucleic acid (PNA) and small-interfer-
ing RNAs (siRNA) are all potential tools to inhibit gene 
expression in ZAAT deficient individuals with liver dis-
ease[49]. Ribozymes are naturally occurring catalytic RNA 
molecules that can cleave target RNA molecules with high 
specificity[50]. Synthetic ribozymes targetting AAT have 
been designed[51]. These contain a catalytic RNA domain 
that cleaves mRNA and a substrate-binding domain spe-
cific for AAT mRNA. Ozaki et al[51] successfully transduced 
human hepatoma cells with ribozymes to inhibit the ex-
pression of  a mutant AAT gene and co-express a modified 
AAT gene that was not sensitive to the ribozyme. This 
gene therapy approach led to inhibition of  the mutant 
gene and expression of  the modified AAT gene; unfortu-
nately the overall efficiency of  this method was low. This is 
a major problem associated with ribozyme use in vivo; their 
activity rarely achieves the desired effect.
PNA are synthetic DNA analogues comprising repeti-
tive units of  the pseudo-peptide polymer N-(2-aminoethyl) 
glycine to which purine and pyrimidine bases are attached 
by a methyl carbonyl linker[52]. PNAs hybridize to comple-
mentary DNA or RNA in a sequence-dependent manner 
leading to anti-gene or antisense inhibition, and blockage of  
transcription or translation, respectively. As PNA oligomers 
are stable and have high binding affinities they constitute 
potentially efficient compounds for gene therapy. Moreover 
they are non-toxic, even at relatively high concentrations al-
though their uptake by living cells is slow. Modification with 
cell penetrating peptides can significantly improve their 
uptake. AAT-directed PNAs can inhibit MAAT expres-
sion in HepG2 cells and human MM monocytes (Greene 
C, unpublished data). They are also capable of  interfer-
ing with ZAAT transgene expression in HEK293 cells or 
endogenous ZAAT gene expression in peripheral blood 
monocytes isolated from ZZ homozygous individuals. Un-
fortunately only partial inhibition can be achieved and the 
approach is considerably less effective than using siRNA.
We have effectively knocked down expression of  
MAAT and ZAAT genes in model systems over-expressing 
these genes and also in human monocytes from MM and 
ZZ homozygous individuals[53]. Others have similarly re-
ported successful knockdown of  AAT in cell lines, and 
have taken the technology further by successfully knocking 
down AAT expression in ZAAT overexpressing transgenic 
mice[54].
Inhibition of polymerisation and enhanced secretion
Peptides designed to block polymerization of  ZAAT rep-
resent important therapies for the treatment ZAAT-related 
liver disease. Mahadeva et al[55] designed a 6-mer peptide 
Phe-Leu-Glu-Ala-Ile-Gly (FLEAIG) that selectively targets 
the reactive centre loop of  ZAAT and blocks its polymer-
ization. A second generation peptide which has the N-acyl 
terminus removed is as effective at inhibiting polymerisa-
tion and yields an active inhibitor[56]. Two additional pep-
tides Ac-FLAAIG-OH and Ac-FLEAAG-OH and their 
daughter 4-mers Ac-FLEAA-NH(2) and Ac-FLAA-NH(2) 
can also bind avidly to ZAAT and prevent polymerization 
of  the protein[57]. In further study using a combinatorial 
approach based on the inhibitory mechanism of  A1AT, 
another peptide developed by Chang et al[58], Ac-TTAI-
NH(2), acts as a tight-binding ligand for ZA1AT. It effec-
tively blocks ZAAT polymerization but can also promote 
dissociation of  the oligomerized serpin.
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4-phenylbutyric acid (4PBA) and glycerol are reagents 
that that can potentially reverse misfolding and enhance 
secretion of  ZAAT. These so-called chemical chaperone 
reagents have potential for targeting ZAAT. 4PBA can 
increase secretion of  ZAAT although the mechanism re-
mains unclear[59], whilst glycerol (and erythritol, trehalose 
and glucose) can interfere with polymerisation of  ZAAT, 
by slowing down conformational transitions of  the pro-
tein. Unfortunately, refolding of  the misfolded conformer 
is usually not possible[60]. Imino sugar compounds includ-
ing castanospermine, kifunensine and deoxymannojirimy-
cin have also been suggested to be useful for enhancing 
ZAAT secretion from cells[61].
CONCLUSION
Accumulation of  ZAAT in the ER has the potential to in-
duce multiple signalling events related to ER stress. Inter-
estingly, although perturbation of  the ER can be induced 
by ZAAT expression in most cells, important differences 
exist in the responses induced in different cell types. The 
next steps in enhancing our understanding of  the mecha-
nisms of  ER stress will be to identify these stimulus- and 
cell-specific responses that occur. Research within the next 
decade is also likely to advance our understanding of  the 
role of  gene modifiers in determining the susceptibility to 
and pathogenesis of  ZAAT-related liver and lung disease. 
This knowledge we will bring us closer to a point where we 
can tailor make specific therapeutics for ZAAT deficient 
individuals. 
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